KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Long-Term Deferred Tax (2019 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed Long-Term Deferred Tax for 7 consecutive years, with $12.9 million as the latest value for Q4 2025.

  • Quarterly Long-Term Deferred Tax rose 33.09% to $12.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $12.9 million through Dec 2025, up 33.09% year-over-year, with the annual reading at $12.9 million for FY2025, 33.09% up from the prior year.
  • Long-Term Deferred Tax for Q4 2025 was $12.9 million at Xenon Pharmaceuticals, up from $11.8 million in the prior quarter.
  • The five-year high for Long-Term Deferred Tax was $12.9 million in Q4 2025, with the low at $207000.0 in Q1 2022.
  • Average Long-Term Deferred Tax over 5 years is $3.2 million, with a median of $572500.0 recorded in 2021.
  • The sharpest move saw Long-Term Deferred Tax crashed 59.73% in 2022, then soared 2619.75% in 2025.
  • Over 5 years, Long-Term Deferred Tax stood at $465000.0 in 2021, then grew by 9.46% to $509000.0 in 2022, then surged by 57.56% to $802000.0 in 2023, then skyrocketed by 1105.24% to $9.7 million in 2024, then surged by 33.09% to $12.9 million in 2025.
  • According to Business Quant data, Long-Term Deferred Tax over the past three periods came in at $12.9 million, $11.8 million, and $11.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.